Morel et al developed a score for evaluating patients with a primary myelodysplastic syndrome based on laboratory and cytogenetic findings. This can help identify patients at increased risk for disease progression. The authors are from Laboratoire d'Hematologie in Lille, France.
Parameters:
(1) karyotype
(2) platelet count
(3) percent blasts in the bone marrow
|
Parameter |
Finding |
Points |
|
karyotype |
not complex |
0 |
|
|
complex |
1 |
|
platelet count |
>= 75,000 per µL |
0 |
|
|
< 75,000 per µL |
1 |
|
percent blasts in the bone marrow |
< 5% |
0 |
|
|
5 - 10% |
1 |
|
|
> 10% |
2 |
where:
• Complex karyotypes included those with at least 3 chromosomes involved (Table 3, page 1319). In the Methods section, complex karyotypes included del 5q with another rearrangement or -7/q- with another rearrangement.
• In the WHO classification percent blasts > 20% indicates AML.
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
|
Total Score |
Risk Group |
Median Survival |
|
0 |
low |
55 months |
|
1 or 2 |
intermediate |
24 months |
|
3 or 4 |
high |
6 months |
A second score was used to determine the risk of progression to AML based on karyotype and percent blasts in the bone marrow.
|
Parameter |
Finding |
Points |
|
karyotype |
not complex |
0 |
|
|
complex (at least 3 chromosomes involved) |
1 |
|
percent blasts in the bone marrow |
<= 10% |
0 |
|
|
> 10% |
1 |
AML risk score =
= SUM(points for both parameters)
Interpretation:
• minimum score: 0
• maximum score: 2
|
Total Score |
Risk Group |
AML free at 2 Years |
|
0 |
low |
92% |
|
1 |
intermediate |
60% |
|
2 |
high |
32% |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
